What a string of semaglutide biosimilars could mean for Mainland China
Clarivate
MAY 14, 2024
A crowded semaglutide biosimilars pipeline is shaping up in Mainland China *Biosimilars of semaglutide include both T2D and obesity patient segments (April 2024) Source: Clarivate Cortellis In a three-way battle, will price beat innovation?
Let's personalize your content